ReviewDiagnostics (Basel, Switzerland)2015
Positron Emission Tomography in Breast Cancer.
Review in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07523516 (Diagnostic Performance of F18-FDG PET/CT in Detecting Distant Metastases in Breast Cancer), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diagnostic Performance of F18-FDG PET/CT in Detecting Distant Metastases in Breast Cancer
Who cites it
16 citing papers in PubMed, 63 citations in OpenAlex.
- Integrating PET/CT-derived heterogeneity indices and composite risk scores improves prognostic stratification in breast cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Application of CAD Systems in Breast Cancer Diagnosis Using Machine Learning Techniques: An Overview of Systematic Reviews.Bioengineering (Basel, Switzerland) · 2025Review
- Evaluating the role of sentinel lymph node biopsy in cT1-2N0M0 breast cancer: a SEER-based study.Gland surgery · 2025Article
- PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.Journal of clinical medicine · 2024Review
- The Role of PET/CT in Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- The Role of Deep Learning in Advancing Breast Cancer Detection Using Different Imaging Modalities: A Systematic Review.Cancers · 2022Review
- Diagnostic Performance of FDG-PET/CT Scan as Compared to US-Guided FNA in Prediction of Axillary Lymph Node Involvement in Breast Cancer Patients.Frontiers in oncology · 2021Article
- Development of Radiotracers for Breast Cancer-The Tumor Microenvironment as an Emerging Target.Cells · 2020Review
- A complementary scheme for automated detection of high-uptake regions on dedicated breast PET and whole-body PET/CT.Radiological physics and technology · 2019Article
- Article
- A Single Simulation Platform for Hybrid Photoacoustic and RF-Acoustic Computed Tomography.Applied sciences (Basel, Switzerland) · 2018Article
- Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.PET clinics · 2018Review
- NoninvasiveJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer.American journal of nuclear medicine and molecular imaging · 2018Article
- Technetium-99m radiolabeled paclitaxel as an imaging probe for breast cancer in vivo.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gradually, FDG-PET/CT has been strengthening within the diagnostic algorithms of oncological diseases. In many of these, PET/CT has shown to be useful at different stages of the disease: diagnosis, staging or re-staging, treatment response assessment, and recurrence. Some of the advantages of this imaging modality versus CT, MRI, bone scan, mammography, or ultrasound, are based on its great diagnostic capacity since, according to the radiopharmaceutical used, it reflects metabolic changes that often occur before morphological changes and therefore allows us to stage at diagnosis. Moreover, another advantage of this technique is that it allows us to evaluate the whole body so it can be very useful for the detection of distant disease. With regard to breast cancer, FDG-PET/CT has proven to be important when recurrence is suspected or in the evaluation of treatment response. The technological advancement of PET equipment through the development of new detectors and equipment designed specifically for breast imaging, and the development of more specific radiopharmaceuticals for the study of the different biological processes of breast cancer, will allow progress not only in making the diagnosis of the disease at an early stage but also in enabling personalized therapy for patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.